OBJECTIVES: The objective of this study was to determine whether constipation-predominant irritable bowel syndrome (IBS-C) is associated with changes in intestinal barrier and secretory function. METHODS: A total of 19 IBS-C patients and 18 healthy volunteers (all females) underwent saccharide excretion assay (0.1 g 13C mannitol and 1 g lactulose), measurements of duodenal and colonic mucosal barrier (transmucosal resistance (TMR), macromolecular and Escherichia coli Bio-Particle translocation), mucosal secretion (basal and acetylcholine (Ach)-evoked short-circuit current (Isc)), in vivo duodenal mucosal impedance, circulating endotoxins, and colonic tight junction gene expression. RESULTS: There were no differences in the in vivo measurements of barrier function between IBS-C patients and healthy controls: cumulative excretion of 13C mannitol (0-2 h mean (s.e.m.); IBS-C: 12.1 (0.9) mg vs. healthy: 13.2 (0.8) mg) and lactulose (8-24 h; IBS-C: 0.9 (0.5) mg vs. healthy: 0.5 (0.2) mg); duodenal impedance IBS-C: 729 (65) Ω vs. healthy: 706 (43) Ω; plasma mean endotoxin activity level IBS-C: 0.36 (0.03) vs. healthy: 0.35 (0.02); and in colonic mRNA expression of occludin, zonula occludens (ZO) 1-3, and claudins 1-12 and 14-19. The ex vivo findings were consistent, with no group differences: duodenal TMR (IBS-C: 28.2 (1.9) Ω cm2 vs. healthy: 29.8 (1.9) Ω cm2) and colonic TMR (IBS-C: 19.1 (1.1) Ω cm2 vs. healthy: 17.6 (1.7) Ω cm2); fluorescein isothiocyanate (FITC)-dextran (4 kDa) and E. coli Bio-Particle flux. Colonic basal Isc was similar, but duodenal basal Isc was lower in IBS-C (43.5 (4.5) μA cm-2) vs. healthy (56.9 (4.9) μA cm-2), P=0.05. Ach-evoked ΔIsc was similar. CONCLUSIONS: Females with IBS-C have normal colonic barrier and secretory function. Basal duodenal secretion is decreased in IBS-C.
OBJECTIVES: The objective of this study was to determine whether constipation-predominant irritable bowel syndrome (IBS-C) is associated with changes in intestinal barrier and secretory function. METHODS: A total of 19 IBS-Cpatients and 18 healthy volunteers (all females) underwent saccharide excretion assay (0.1 g 13C mannitol and 1 g lactulose), measurements of duodenal and colonic mucosal barrier (transmucosal resistance (TMR), macromolecular and Escherichia coli Bio-Particle translocation), mucosal secretion (basal and acetylcholine (Ach)-evoked short-circuit current (Isc)), in vivo duodenal mucosal impedance, circulating endotoxins, and colonic tight junction gene expression. RESULTS: There were no differences in the in vivo measurements of barrier function between IBS-Cpatients and healthy controls: cumulative excretion of 13C mannitol (0-2 h mean (s.e.m.); IBS-C: 12.1 (0.9) mg vs. healthy: 13.2 (0.8) mg) and lactulose (8-24 h; IBS-C: 0.9 (0.5) mg vs. healthy: 0.5 (0.2) mg); duodenal impedance IBS-C: 729 (65) Ω vs. healthy: 706 (43) Ω; plasma mean endotoxin activity level IBS-C: 0.36 (0.03) vs. healthy: 0.35 (0.02); and in colonic mRNA expression of occludin, zonula occludens (ZO) 1-3, and claudins 1-12 and 14-19. The ex vivo findings were consistent, with no group differences: duodenal TMR (IBS-C: 28.2 (1.9) Ω cm2 vs. healthy: 29.8 (1.9) Ω cm2) and colonicTMR (IBS-C: 19.1 (1.1) Ω cm2 vs. healthy: 17.6 (1.7) Ω cm2); fluorescein isothiocyanate (FITC)-dextran (4 kDa) and E. coli Bio-Particle flux. Colonic basal Isc was similar, but duodenal basal Isc was lower in IBS-C (43.5 (4.5) μA cm-2) vs. healthy (56.9 (4.9) μA cm-2), P=0.05. Ach-evoked ΔIsc was similar. CONCLUSIONS: Females with IBS-C have normal colonic barrier and secretory function. Basal duodenal secretion is decreased in IBS-C.
Authors: C P Kelly; P H R Green; J A Murray; A Dimarino; A Colatrella; D A Leffler; T Alexander; R Arsenescu; F Leon; J G Jiang; L A Arterburn; B M Paterson; R N Fedorak Journal: Aliment Pharmacol Ther Date: 2012-11-19 Impact factor: 8.171
Authors: David A Katzka; Karthik Ravi; Debra M Geno; Thomas C Smyrk; Prasad G Iyer; Jeffrey A Alexander; Jerry E Mabary; Michael Camilleri; Michael F Vaezi Journal: Clin Gastroenterol Hepatol Date: 2015-01-13 Impact factor: 11.382
Authors: T Piche; G Barbara; P Aubert; S Bruley des Varannes; R Dainese; J L Nano; C Cremon; V Stanghellini; R De Giorgio; J P Galmiche; M Neunlist Journal: Gut Date: 2008-09-29 Impact factor: 23.059
Authors: Jung Ho Park; Dong Il Park; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Kyoung Hee Won; Soon Min Park Journal: Gut Liver Date: 2009-09-30 Impact factor: 4.519
Authors: Onur Cil; Puay-Wah Phuan; Sujin Lee; Joseph Tan; Peter M Haggie; Marc H Levin; Liang Sun; Jay R Thiagarajah; Tonghui Ma; A S Verkman Journal: Cell Mol Gastroenterol Hepatol Date: 2016-01-09
Authors: Olga Bednarska; Susanna A Walter; Maite Casado-Bedmar; Magnus Ström; Eloísa Salvo-Romero; Maria Vicario; Emeran A Mayer; Åsa V Keita Journal: Gastroenterology Date: 2017-07-13 Impact factor: 22.682
Authors: Shoko Edogawa; Stephanie A Peters; Gregory D Jenkins; Sakteesh V Gurunathan; Wendy J Sundt; Stephen Johnson; Ryan J Lennon; Roy B Dyer; Michael Camilleri; Purna C Kashyap; Gianrico Farrugia; Jun Chen; Ravinder J Singh; Madhusudan Grover Journal: FASEB J Date: 2018-06-13 Impact factor: 5.191
Authors: George B Saffouri; Robin R Shields-Cutler; Jun Chen; Yi Yang; Heather R Lekatz; Vanessa L Hale; Janice M Cho; Eric J Battaglioli; Yogesh Bhattarai; Kevin J Thompson; Krishna K Kalari; Gaurav Behera; Jonathan C Berry; Stephanie A Peters; Robin Patel; Audrey N Schuetz; Jeremiah J Faith; Michael Camilleri; Justin L Sonnenburg; Gianrico Farrugia; Jonathan R Swann; Madhusudan Grover; Dan Knights; Purna C Kashyap Journal: Nat Commun Date: 2019-05-01 Impact factor: 14.919
Authors: Ju Yup Lee; Nayoung Kim; Ji Hyun Park; Ryoung Hee Nam; Sun Min Lee; Chin-Hee Song; Geun Kim; Hee Young Na; Yoon Jin Choi; Jin Joo Kim; Dong Ho Lee Journal: J Neurogastroenterol Motil Date: 2020-01-30 Impact factor: 4.924